Division of Cardiology, Cardiac Center, the Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Cardiovascular Outcomes, Quality, and Evaluative Research Center, University of Pennsylvania, Philadelphia, Pennsylvania; Leonard Davis Institute for Healthcare Economics, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Biomedical Health Informatics, Data Science and Biostatistics Unit, the Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
J Heart Lung Transplant. 2021 Nov;40(11):1443-1453. doi: 10.1016/j.healun.2021.06.003. Epub 2021 Jun 11.
Mechanical circulatory support (MCS) is increasingly being used as a bridge to transplant in pediatric patients. We compare outcomes in pediatric patients bridged to transplant with MCS from an international cohort.
This retrospective cohort study of heart-transplant patients reported to the International Society for Heart and Lung Transplantation (ISHLT) registry from 2005-2017 includes 5,095 patients <18 years. Pretransplant MCS exposure and anatomic diagnosis were derived. Outcomes included mortality, renal failure, and stroke.
26% of patients received MCS prior to transplant: 240 (4.7%) on extracorporeal membrane oxygenation (ECMO), 1,030 (20.2%) on ventricular assist device (VAD), and 54 (1%) both. 29% of patients were <1 year, and 43.8% had congenital heart disease (CHD). After adjusting for clinical characteristics, compared to no-MCS and VAD, ECMO had higher mortality during their transplant hospitalization [OR 3.97 & 2.55; 95% CI 2.43-6.49 & 1.42-4.60] while VAD mortality was similar [OR 1.55; CI 0.99-2.45]. Outcomes of ECMO+VAD were similar to ECMO alone, including increased mortality during transplant hospitalization compared to no-MCS [OR 4.74; CI 1.81-12.36]. Patients with CHD on ECMO had increased 1 year, and 10 year mortality [HR 2.36; CI 1.65-3.39], [HR 1.82; CI 1.33-2.49]; there was no difference in survival in dilated cardiomyopathy (DCM) patients based on pretransplant MCS status.
Survival in CHD and DCM is similar in patients with no MCS or VAD prior to transplant, while pretransplant ECMO use is strongly associated with mortality after transplant particularly in children with CHD. In children with DCM, long term survival was equivalent regardless of MCS status.
机械循环支持(MCS)越来越多地被用作儿科患者移植的桥接方法。我们比较了国际队列中接受 MCS 桥接移植的儿科患者的结局。
这项回顾性队列研究纳入了 2005 年至 2017 年向国际心肺移植协会(ISHLT)登记处报告的 5095 名<18 岁的心脏移植患者。分析了移植前 MCS 暴露和解剖诊断。结果包括死亡率、肾功能衰竭和中风。
26%的患者在移植前接受了 MCS:240 例(4.7%)接受体外膜氧合(ECMO),1030 例(20.2%)接受心室辅助装置(VAD),54 例(1%)同时接受两种治疗。29%的患者<1 岁,43.8%患有先天性心脏病(CHD)。调整临床特征后,与无 MCS 和 VAD 相比,ECMO 在移植住院期间的死亡率更高[比值比(OR)3.97 和 2.55;95%置信区间(CI)2.43-6.49 和 1.42-4.60],而 VAD 的死亡率相似[OR 1.55;CI 0.99-2.45]。ECMO+VAD 的结局与 ECMO 单独治疗相似,包括与无 MCS 相比,移植住院期间的死亡率增加[OR 4.74;CI 1.81-12.36]。接受 ECMO 的 CHD 患者 1 年和 10 年死亡率均增加[风险比(HR)2.36;CI 1.65-3.39],[HR 1.82;CI 1.33-2.49];在接受移植前 MCS 治疗的扩张型心肌病(DCM)患者中,生存率没有差异。
在接受移植前无 MCS 或 VAD 的 CHD 和 DCM 患者中,生存率相似,而移植前 ECMO 的使用与移植后死亡率密切相关,特别是在 CHD 患儿中。在 DCM 患儿中,无论 MCS 状态如何,长期生存率均相当。